BioPharmSignal logoBioPharmSignal

Biotech News

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Adial Pharmaceuticals (ADIL)Adial PharmaceuticalsCompany update

Expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence

CHARLOTTESVILLE, Va., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage...

Related news

ADILAdial Pharmaceuticals2024-02-28 09:30 EST

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

ADILAdial Pharmaceuticals2024-04-22 08:30 EST

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

View all latest news

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.

Recent company news

ADILAdial Pharmaceuticals2025-06-11 08:00 EST

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

ADILAdial Pharmaceuticals2025-05-15 08:30 EST

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ADILAdial Pharmaceuticals2025-05-13 08:30 EST

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

ADILAdial Pharmaceuticals2025-05-08 08:30 EST

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

ADILAdial Pharmaceuticals2025-05-02 11:48 EST

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Stock data

Close
6.22 USD
Market cap
5.06M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States